Repository logo
 
Publication

The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis

2023-06Journal article Open access
Simple item page
dc.contributor.authorEstarreja, João
dc.contributor.authorMendes, Priscila
dc.contributor.authorSilva, Carina
dc.contributor.authorCamacho, Pedro
dc.contributor.authorMateus, Vanessa
dc.date.accessioned2023-07-05T09:09:29Z
dc.date.available2023-07-05T09:09:29Z
dc.date.issued2023-06
dc.descriptionFCT_UIDB/05608/2020. FCT_UIDP/05608/2020.pt_PT
dc.description.abstractBackground: Age-related macular degeneration (AMD) is recognized as the leading cause of vision loss in older people. Considering the phenomenon of aging societies worldwide, the prevalence of AMD is expected to increase gradually in the future. AMD can be divided into early, intermediate, and late stages, with the early and intermediate stages being mainly asymptomatic, and the late stage being classified as geographic atrophy, neovascular AMD, or both. Current pharmacological treatments for neovascular AMD include anti-vascular endothelial growth factors agents, such as ranibizumab, pegaptanib, and aflibercept. Additionally, it has been reported that the off-label use of intravitreally administered bevacizumab is effective. It is also lower cost than other agents, which makes it an interesting pharmacological approach. Objective: This review aims to evaluate the efficacy, safety, and efficiency of bevacizumab for the treatment of neovascular AMD. Methods: This review will only consider randomized controlled clinical trials that compare the use of bevacizumab with another pharmacological agent or placebo in patients aged 50 years and older who are diagnosed with vascular AMD. It will exclude studies that include participants diagnosed with polypoidal choroidal vasculopathy or retinal angiomatous proliferation. To identify and select relevant articles, we will develop a highly sensitive search strategy and apply it in MEDLINE via the PubMed platform. Upon selection of the studies and analysis of the titles, abstracts, and full texts, the results will be presented according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The analysis and extraction of the data will be performed by 2 independent reviewers. The risk of bias will be evaluated with the Critical Appraisal Skills Programme (CASP) checklist. Finally, the same reviewers will also perform a quality assessment of the included studies with the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) tool. Results: The search strategy, after the application of the inclusion and exclusion criteria, identified 15 randomized clinical trials, which are currently being analyzed. This project has no funding and it has been developed by a multidisciplinary research team of pharmacologists and orthoptists. The study was initiated in May 2021 and it is expected to conclude by the end of 2023. Conclusions: This review will provide a synthesis of current information and underlying evidence about the off-label use of bevacizumab in neovascular AMD. It will provide a clearer vision of a possible new pharmacological approach, as well as the most suitable treatment designs, for the treatment of neovascular AMD.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEstarreja J, Mendes P, Silva C, Camacho P, Mateus V. The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis. JMIR Res Protoc. 2023;12:e38658.pt_PT
dc.identifier.doi10.2196/38658pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/16279
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherJMIR Publicationspt_PT
dc.relation.publisherversionhttps://www.researchprotocols.org/2023/1/e38658pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectOphthalmologypt_PT
dc.subjectAge-related macular degenerationpt_PT
dc.subjectBevacizumabpt_PT
dc.subjectDrug therapypt_PT
dc.subjectnAMDpt_PT
dc.subjectNeovascular age-related macular degenerationpt_PT
dc.subjectWet macular degenerationpt_PT
dc.subjectFCT_UIDB/05608/2020pt_PT
dc.subjectFCT_UIDP/05608/2020pt_PT
dc.titleThe efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPagee38658pt_PT
oaire.citation.titleJMIR Research Protocolspt_PT
oaire.citation.volume12pt_PT
person.familyNameEstarreja
person.familyNameRodrigues Gomes Mendes
person.familyNameSilva
person.familyNameCamacho
person.familyNamePinho Mateus
person.givenNameJoão
person.givenNamePriscila
person.givenNameCarina
person.givenNamePedro
person.givenNameVanessa Alexandra
person.identifier.ciencia-idEB19-EDA2-704B
person.identifier.ciencia-id6A16-5C18-F10B
person.identifier.ciencia-id2411-5936-0820
person.identifier.ciencia-id271F-B4E1-014E
person.identifier.ciencia-id5A12-571D-AD6A
person.identifier.orcid0000-0002-8283-3174
person.identifier.orcid0000-0002-0013-3140
person.identifier.orcid0000-0003-1021-7935
person.identifier.orcid0000-0002-2986-5652
person.identifier.orcid0000-0002-3204-3772
person.identifier.scopus-author-id55258764900
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationd16a20d0-ac73-4989-b83d-abeab53139f7
relation.isAuthorOfPublicationb02faa18-658e-4edc-b846-7c0b3646414c
relation.isAuthorOfPublication81a5cd80-1982-43ba-bde5-4c43ae0e5234
relation.isAuthorOfPublicationc41e9c52-157e-4375-8005-b609cfc374e7
relation.isAuthorOfPublication406041a5-682c-4f94-a4e2-ddbfc541313c
relation.isAuthorOfPublication.latestForDiscovery406041a5-682c-4f94-a4e2-ddbfc541313c

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration_protocol for a systematic review and meta-analysis.pdf
Size:
105.03 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos